Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide
- 15 August 2008
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 48 (5) , 572-576
- https://doi.org/10.1097/qai.0b013e31817bbc4e
Abstract
Objectives: To estimate the in vivo fitness cost of enfuvirtide (ENF) resistance, we analyzed dynamic shifts in the HIV-1 quasispecies under changing selective pressure in 3 subjects on failing ENF-based regimens who interrupted ENF while maintaining stable background regimens. Subsequently, ENF was readministered for 4 weeks as “pulse intensification.” Methods: The proportion of plasma virus carrying the V38A mutation in gp41 was quantified by allele-specific real-time polymerase chain reaction in serial samples collected from 3 subjects at 1- to 4-week intervals. Fitness differences were calculated using a method that corrected for time dependence of the viral replication rate. Results: The V38A mutant made up ≥85% of the quasispecies at baseline and decayed to <5% over 12-24 weeks; plasma HIV-1 RNA levels remained stable during this time. Fitness differences for mutant versus wild type ranged from −25% to −65%, providing in vivo evidence for the reduced fitness of ENF-resistant HIV-1. The V38A mutant virus reemerged rapidly during the ENF pulse. Conclusions: These results demonstrate that the HIV-1 quasispecies undergoes dynamic changes in response to withdrawal and reinitiation of fusion inhibitor therapy. The relative stability of plasma HIV-1 titers during decay of V38A suggests that factors other than viral fitness likely define viral load set-point in patients with advanced disease.Keywords
This publication has 25 references indexed in Scilit:
- Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapyAIDS, 2007
- Interruption of Enfuvirtide in HIV‐1–Infected Adults with Incomplete Viral Suppression on an Enfuvirtide‐Based RegimenThe Journal of Infectious Diseases, 2007
- Role of the Envelope Genetic Context in the Development of Enfuvirtide Resistance in Human Immunodeficiency Virus Type 1-Infected PatientsJournal of Virology, 2006
- Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatmentJournal of Antimicrobial Chemotherapy, 2006
- Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapyAIDS, 2006
- T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral TherapyThe Journal of Infectious Diseases, 2003
- Procedures for reliable estimation of viral fitness from time-series dataProceedings Of The Royal Society B-Biological Sciences, 2002
- Evolution of Human Immunodeficiency Virus Type 1 Populations after Resumption of Therapy following Treatment Interruption and Shift in Resistance GenotypeThe Journal of Infectious Diseases, 2002
- Evaluation of Distinct Blood Lymphocyte Populations in Human Immunodeficiency Virus Type 1–Infected Subjects in the Absence or Presence of Effective TherapyThe Journal of Infectious Diseases, 1999
- Competition between zidovudine-sensitive and zidovudine-resistant strains of HIVAIDS, 1992